Magna graecia sufficient velocity quests
The MTT assay, live/dead staining of cells, and H&E-staining indicate the non-toxicity and biosafety of our ES-MION9. T 1 -weighted MR images of aqueous solutions, cells and tumor-bearing mice at 3.0 T or 7.0 T demonstrate that our ES-MION9 has a stronger capability of enhancing the MRI contrast comparing with the commercial Gd chelates. The pharmacokinetics and biodistribution of ES-MION9 in vivo demonstrate the better tumor targetability and MRI time window of ES-MION9 than commercial Gd chelates. The ES-MION9 has excellent water dispersibility because of the excessive –COOH from the stabilizer PASP. After optimization of the synthesis conditions, the final obtained ES-MION9 with 3.7 nm of diameter has a high r 1 value (7.0 ± 0.4 mM ⁻¹ s ⁻¹ ) and a low r 2 / r 1 ratio (4.9 ± 0.6) at 3.0 T. To overcome the problems of commercial Gd chelates-based T 1 CAs, commercial magnetic iron oxide nanoparticles (MIONs)-based T 2 CAs, and reported exceedingly small MIONs (ES-MIONs)-based T 1 CAs, in this study, a facile co-precipitation method was developed to synthesize biodegradable and biocompatible ES-MIONs with excellent water-dispersibility using poly (aspartic acid) (PASP) as a stabilizer for T 1 -weighted MRI of tumors. Magnetic resonance imaging (MRI) has been widely using in clinical diagnosis, and contrast agents (CAs) can improve the sensitivity MRI. Thus, nanoscale confinement offers a new and general strategy for enhancing the contrast of gadolinium-based contrast agents. The enhancement in contrast is attributed to the geometrical confinement of the agents, which influences the paramagnetic behaviour of the Gd(3+) ions. These relaxivity values are about 4 to 50 times larger than those of clinically available gadolinium-based agents (∼ 4 mM(-1) s(-1)/Gd(3+) ion). Magnevist, gadofullerenes and gadonanotubes were loaded inside the pores of quasi-hemispherical and discoidal particles.
Here, we show a general method for increasing relaxivity by confining contrast agents inside the nanoporous structure of silicon particles. Magnetic resonance imaging contrast agents are currently designed by modifying their structural and physiochemical properties to improve relaxivity and to enhance image contrast.